Targeted Therapies for Brain Metastases from Breast Cancer

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2016 Sep 21

PMID 27649142

Citations 49

Authors

Vyshak Alva Venur

Jose Pablo Leone

Affiliations

Soon will be listed here.

Abstract

The discovery of various driver pathways and targeted small molecule agents/antibodies have revolutionized the management of metastatic breast cancer. Currently, the major targets of clinical utility in breast cancer include the human epidermal growth factor receptor 2 (HER2) and epidermal growth factor receptor (EGFR), vascular endothelial growth factor (VEGF) receptor, mechanistic target of rapamycin (mTOR) pathway, and the cyclin-dependent kinase 4/6 (CDK-4/6) pathway. Brain metastasis, however, remains a thorn in the flesh, leading to morbidity, neuro-cognitive decline, and interruptions in the management of systemic disease. Approximately 20%-30% of patients with metastatic breast cancer develop brain metastases. Surgery, whole brain radiation therapy, and stereotactic radiosurgery are the traditional treatment options for patients with brain metastases. The therapeutic paradigm is changing due to better understanding of the blood brain barrier and the advent of tyrosine kinase inhibitors and monoclonal antibodies. Several of these agents are in clinical practice and several others are in early stage clinical trials. In this article, we will review the common targetable pathways in the management of breast cancer patients with brain metastases, and the current state of the clinical development of drugs against these pathways.

Citing Articles

Real life outcome analysis of breast cancer brain metastases treated with Trastuzumab Deruxtecan.

Fabi A, Rossi A, Caputo R, Pisegna S, Scagnoli S, Pantano F NPJ Precis Oncol. 2025; 9(1):22.

PMID: 39843642 PMC: 11754752. DOI: 10.1038/s41698-025-00801-3.

Fractionated stereotactic radiotherapy of brainstem metastases - Clinical outcome and prognostic factors.

Kramer A, Hahnemann L, Schunn F, Grott C, Thomas M, Christopoulos P Clin Transl Radiat Oncol. 2024; 50:100893.

PMID: 39651456 PMC: 11621500. DOI: 10.1016/j.ctro.2024.100893.

Stereotactic radiosurgery for brain metastases from human epidermal receptor 2 positive breast Cancer: an international, multi-center study.

Pikis S, Mantziaris G, Protopapa M, Tos S, Kowalchuk R, Ross R J Neurooncol. 2024; 170(1):199-208.

PMID: 39192068 PMC: 11446965. DOI: 10.1007/s11060-024-04775-3.

Exosomal lncRNAs as regulators of breast cancer chemoresistance and metastasis and their potential use as biomarkers.

Blancas-Zugarazo S, Langley E, Hidalgo-Miranda A Front Oncol. 2024; 14:1419808.

PMID: 39148900 PMC: 11324554. DOI: 10.3389/fonc.2024.1419808.

Brain Radiotherapy Combined with Targeted Therapy for HER2-Positive Breast Cancer Patients with Brain Metastases.

Tang L, Zhang W, Chen L Breast Cancer (Dove Med Press). 2024; 16:379-392.

PMID: 39071808 PMC: 11278000. DOI: 10.2147/BCTT.S460856.

References

Samuels Y, Ericson K . Oncogenic PI3K and its role in cancer. Curr Opin Oncol. 2005; 18(1):77-82. DOI: 10.1097/01.cco.0000198021.99347.b9. View

Song M, Salmena L, Pandolfi P . The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 13(5):283-96. DOI: 10.1038/nrm3330. View

Baselga J, Campone M, Piccart M, Burris 3rd H, Rugo H, Sahmoud T . Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 2011; 366(6):520-9. PMC: 5705195. DOI: 10.1056/NEJMoa1109653. View

Verma S, Miles D, Gianni L, Krop I, Welslau M, Baselga J . Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med. 2012; 367(19):1783-91. PMC: 5125250. DOI: 10.1056/NEJMoa1209124. View

Freedman R, Bullitt E, Sun L, Gelman R, Harris G, Ligibel J . A phase II study of sagopilone (ZK 219477; ZK-EPO) in patients with breast cancer and brain metastases. Clin Breast Cancer. 2011; 11(6):376-83. PMC: 3773692. DOI: 10.1016/j.clbc.2011.03.024. View

Le Scodan R, Jouanneau L, Massard C, Gutierrez M, Kirova Y, Cherel P . Brain metastases from breast cancer: prognostic significance of HER-2 overexpression, effect of trastuzumab and cause of death. BMC Cancer. 2011; 11:395. PMC: 3185282. DOI: 10.1186/1471-2407-11-395. View

de Vries N, Zhao J, Kroon E, Buckle T, Beijnen J, van Tellingen O . P-glycoprotein and breast cancer resistance protein: two dominant transporters working together in limiting the brain penetration of topotecan. Clin Cancer Res. 2007; 13(21):6440-9. DOI: 10.1158/1078-0432.CCR-07-1335. View

Lin N, Dieras V, Paul D, Lossignol D, Christodoulou C, Stemmler H . Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res. 2009; 15(4):1452-9. DOI: 10.1158/1078-0432.CCR-08-1080. View

Miles D, Dieras V, Cortes J, Duenne A, Yi J, OShaughnessy J . First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol. 2013; 24(11):2773-80. DOI: 10.1093/annonc/mdt276. View

10.

Lim E, Lin N . Updates on the management of breast cancer brain metastases. Oncology (Williston Park). 2014; 28(7):572-8. View

11.

Pestalozzi B, Brignoli S . Trastuzumab in CSF. J Clin Oncol. 2000; 18(11):2349-51. DOI: 10.1200/JCO.2000.18.11.2349. View

12.

Sperduto P, Berkey B, Gaspar L, Mehta M, Curran W . A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2007; 70(2):510-4. DOI: 10.1016/j.ijrobp.2007.06.074. View

13.

Choi Y, Anders L . Signaling through cyclin D-dependent kinases. Oncogene. 2013; 33(15):1890-903. DOI: 10.1038/onc.2013.137. View

14.

Mehta M, Paleologos N, Mikkelsen T, Robinson P, Ammirati M, Andrews D . The role of chemotherapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2009; 96(1):71-83. PMC: 2808518. DOI: 10.1007/s11060-009-0062-7. View

15.

Walshe J, Denduluri N, Berman A, Rosing D, Swain S . A phase II trial with trastuzumab and pertuzumab in patients with HER2-overexpressed locally advanced and metastatic breast cancer. Clin Breast Cancer. 2006; 6(6):535-9. DOI: 10.3816/CBC.2006.n.009. View

16.

Romond E, Perez E, Bryant J, Suman V, Geyer Jr C, Davidson N . Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med. 2005; 353(16):1673-84. DOI: 10.1056/NEJMoa052122. View

17.

Cox M, Dan T, Swain S . Emerging drugs to replace current leaders in first-line therapy for breast cancer. Expert Opin Emerg Drugs. 2006; 11(3):489-501. DOI: 10.1517/14728214.11.3.489. View

18.

Andre F, ORegan R, Ozguroglu M, Toi M, Xu B, Jerusalem G . Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Oncol. 2014; 15(6):580-91. DOI: 10.1016/S1470-2045(14)70138-X. View

19.

Lin N, Carey L, Liu M, Younger J, Come S, Ewend M . Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol. 2008; 26(12):1993-9. PMC: 4524351. DOI: 10.1200/JCO.2007.12.3588. View

20.

Lee J, Loh K, Yap Y . PI3K/Akt/mTOR inhibitors in breast cancer. Cancer Biol Med. 2016; 12(4):342-54. PMC: 4706528. DOI: 10.7497/j.issn.2095-3941.2015.0089. View